Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

122P - Serum PDL-1 in colorectal cancer

Date

17 Sep 2020

Session

E-Poster Display

Topics

Targeted Therapy

Tumour Site

Colon and Rectal Cancer

Presenters

Lyudmila Akhmaltdinova

Citation

Annals of Oncology (2020) 31 (suppl_4): S274-S302. 10.1016/annonc/annonc266

Authors

L.L. Akhmaltdinova1, D. Babenko2, V. Zhumaliyeva3, I. Kadyrova4, Y. Kolesnikova5, A. Turmukhambetova6, V. Sirota3

Author affiliations

  • 1 Shared Resource Lab, Karaganda Medical University, 100008 - Karaganda/KZ
  • 2 Shared Laboratory Of Research And Scientific Center, Karaganda Medical University, 100008 - Karaganda/KZ
  • 3 Department Of Oncology, Karaganda Medical University, 100008 - Karaganda/KZ
  • 4 Shared Resource Lab, Karaganda State Medical University, 100008 - Karaganda/KZ
  • 5 Department Of Biochemistry, Karaganda Medical University, 100008 - Karaganda/KZ
  • 6 Administration, Karaganda Medical University, 100008 - Karaganda/KZ

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 122P

Background

The PD-1/PDL-1 system is one of the most notable breakthroughs in understanding the nature of cancer in recent years. The 2018 Nobel Prize was followed by a flurry of research. Expression of PD-L1 is often observed in human cancer. Serum level is an easy way to evaluate the immune regulation of tumor growth. But how useful is it for colorectal cancer?

Methods

The Control Group: 97 people Me(Q1;Q3), aged 58 (45;67), conditionally healthy individuals according to the medical examination. The experimental group including 309 patients aged 66(60;72) were diagnosed with colorectal cancer (adenocarcinoma). For the study, we used the the XMap technology, kit PD-L1 Human ProcartaPlex Kit.

Results

In a study of the general group with colorectal cancer, the PDL-1 marker was found to be 31.12 (0.0; 42.5) pg/ml vs. 10.07 (3.0; 32.5) pg/ml in the control group (p=0.03). The sensitivity was 78.8%, but the specificity was 37% (cut-off of 6.9 pg/ml). At the same time, after surgical treatment (after 1 week), it fell catastrophically to 5.96 (3,1;9.7) pg/ml (p=0.00). Studying the level of PDL1 on the different stage of the cancer, it was found that PDL-1 has not an explicit link with stage (I -32.38(0.0; 40.9) pg/ml; II - 31.37(0.0;44.5) pg/ml; III -29.9(0.0;37.4)pg/ml, IV- 38.45(0.0;44.5)pg/ml). Control vs. I, II, II, IV stage p=0,08; 0,016; 0,032; 0,048. PDL1 level depending on the degree of adenocarcinoma differentiation shows the size of the groups does not allow reaching significance with G1 30,36(1,4; 38,46)pg/ml, however, while G2 33,14 (3,5; 44,0)pg/ml vs. Control p = 0.00; G3 35,42(20,9; 46,39)pg/ml vs. control p = 0.00.

Conclusions

Even though this indicator is highly variable, Serum PD-L1 has shown itself to be a promising marker for tumor growth.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Karaganda Medical University.

Funding

STP O.0821 “Personified approach to the management of a number of significant diseases” funded by the Ministry of Education and Science of the Republic of Kazakhstan.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.